BMI
MCID: BDY007
MIFTS: 48

Body Mass Index Quantitative Trait Locus 1 (BMI)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 58 13
Body Mass Index 58 3 17
Bmi 58 49 3
Body Mass Index; Bmi 58
Bmiq1 58

Classifications:



External Ids:

OMIM 58 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM : 58 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). For discussion of genetic heterogeneity of BMI quantitative trait loci and their known or possible associations with variation in specific genes, see MAPPING and MOLECULAR GENETICS sections. (606641)

MalaCards based summary : Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 10 and body mass index quantitative trait locus 18. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Leuprolide and Morphine have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and liver.

CDC : 3 Adult BMI Calculator

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 654)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 10 12.7
2 body mass index quantitative trait locus 18 12.7
3 body mass index quantitative trait locus 11 12.7
4 body mass index quantitative trait locus 8 12.6
5 body mass index quantitative trait locus 7 12.6
6 body mass index quantitative trait locus 14 12.6
7 body mass index quantitative trait locus 19 12.6
8 body mass index quantitative trait locus 9 12.5
9 body mass index quantitative trait locus 4 12.5
10 body mass index quantitative trait locus 12 12.5
11 body mass index quantitative trait locus 2 12.5
12 body mass index quantitative trait locus 3 12.5
13 body mass index quantitative trait locus 5 12.5
14 body mass index quantitative trait locus 6 12.5
15 body mass index quantitative trait locus 13 12.5
16 body mass index quantitative trait locus 15 12.5
17 body mass index quantitative trait locus 20 12.5
18 esophageal cancer 11.4
19 chromosome 16p11.2 deletion syndrome, 220-kb 11.4
20 cone-rod dystrophy and hearing loss 2 11.1
21 mental retardation, x-linked 12 11.1
22 morbid obesity and spermatogenic failure 11.1
23 diabetes mellitus 10.8
24 liver disease 10.6
25 gestational diabetes 10.6
26 rere-related disorders 10.5
27 fatty liver disease 10.5
28 anorexia nervosa 10.5
29 asthma 10.5
30 nonalcoholic fatty liver disease 10.5
31 rheumatoid arthritis 10.5
32 atrial fibrillation 10.5
33 lung cancer 10.4
34 kidney disease 10.4
35 adenocarcinoma 10.4
36 psoriasis 10.4
37 coronary heart disease 1 10.4
38 chronic kidney failure 10.4
39 lipid metabolism disorder 10.4
40 precocious puberty 10.4
41 alzheimer disease 10.4
42 arteries, anomalies of 10.4
43 hepatitis 10.4
44 lymphoma 10.4
45 pre-eclampsia 10.4
46 anxiety 10.3
47 breast reconstruction 10.3
48 sleep apnea 10.3
49 myocardial infarction 10.3
50 bipolar disorder 10.3

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM:

606641

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53714-56-0 657181 3911
2
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
4
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
5
Chlorhexidine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 55-56-1 2713 9552079
6
Coal tar Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 8007-45-2
7
Meperidine Approved Phase 4,Phase 3 57-42-1 4058
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Ketoprofen Approved, Vet_approved Phase 4,Phase 1 22071-15-4 3825
10
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Nitric Oxide Approved Phase 4,Phase 1,Not Applicable 10102-43-9 145068
13
Povidone-iodine Approved Phase 4,Phase 2,Phase 3,Not Applicable 25655-41-8
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
15
Povidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 9003-39-8
16
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
17
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 46507594 772
18
Clopidogrel Approved Phase 4,Phase 2 120202-66-6, 113665-84-2 60606
19
Ticagrelor Approved Phase 4,Phase 2 274693-27-5 9871419
20
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
21
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
22
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
23
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 68-04-2
24
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
25
Calcium Carbonate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 471-34-1
26
Liraglutide Approved Phase 4,Phase 3,Not Applicable 204656-20-2 44147092
27
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53608-75-6
28
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7440-66-6 32051
30
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
31
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
32
Ziprasidone Approved Phase 4,Phase 3,Phase 1,Not Applicable 146939-27-7 60854
33
Chromium Approved Phase 4,Phase 3,Not Applicable 7440-47-3 27668
34
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
35
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
36
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
37
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
38
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
39
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
40
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-78-2 2244
41
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
42
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 112809-51-5 3902
43
Cetrorelix Approved, Investigational Phase 4,Not Applicable 120287-85-6 25074887 16129715
44
Telmisartan Approved, Investigational Phase 4,Not Applicable 144701-48-4 65999
45
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 57-83-0 5994
46
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Not Applicable 116094-23-6 16132418
47
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Not Applicable 133107-64-9
48
Glucagon Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 16941-32-5
49
Magnesium oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 1309-48-4 14792
50
Nicotine Approved Phase 4,Phase 3,Phase 2,Not Applicable 54-11-5 89594 942

Interventional clinical trials:

(show top 50) (show all 4435)
# Name Status NCT ID Phase Drugs
1 Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
2 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
3 Evaluation of a Family Intervention Program for the Management of Overweight or Obese Children Unknown status NCT01878994 Phase 4
4 Children's Healthy Living Program Unknown status NCT01881373 Phase 4
5 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
6 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
7 Treatment of Periodontitis in Obese Individuals Unknown status NCT03103204 Phase 4
8 Intraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication Unknown status NCT01558622 Phase 4 dexketoprofen trometamol;tramadol hydrochloride;pethidine hydrochloride;dexketoprofen trometamol + tramadol hydrochloride;dexketoprofen trometamol + pethidine hydrochloride;vitamin c
9 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
10 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
11 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
12 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity Unknown status NCT00327912 Phase 4
13 Body Composition Measurements in Chronic Heart Failure Unknown status NCT02686866 Phase 4
14 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
15 L-arginine Treatment in Mild Hypertension Unknown status NCT02894723 Phase 4
16 Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
17 The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity Unknown status NCT01405352 Phase 4
18 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
19 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
20 The Therapeutic Effect of Catgut Embedding in Obesity Unknown status NCT02276235 Phase 4
21 Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment Unknown status NCT01865448 Phase 4
22 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
23 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
24 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
25 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
26 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
27 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Unknown status NCT02169570 Phase 4
28 LPD+α-ketoacids on Autophagy and Improving Muscle Wasting in CKD Unknown status NCT02568020 Phase 4 keto-amino acids
29 Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
30 Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me" Unknown status NCT02169024 Phase 4
31 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
32 Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study Unknown status NCT01962402 Phase 4 lorcaserin
33 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
34 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
35 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
36 Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
37 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine
38 Oral Contraceptives and Body Mass Index Completed NCT01170390 Phase 4 All participants (Aviane);Portia;Aviane
39 Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27 Completed NCT01509365 Phase 4 clopidogrel;clopidogrel
40 The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. Completed NCT00356148 Phase 4 Ampicillin/Sulbactam
41 Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years Recruiting NCT03338296 Phase 4 lorcaserin hydrochloride XR;Placebo
42 A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents Not yet recruiting NCT03922945 Phase 4 VI-0521 oral capsule;Placebo oral capsule
43 Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI) Completed NCT01481740 Phase 4 Phenylephrine bolus;phenylephrine infusion
44 Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
45 Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes Completed NCT01232491 Phase 4 Insulin detemir
46 Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed NCT00203450 Phase 4 Zonegran;Placebo
47 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4
48 The Effect of Some Parturients' Characteristics on Sensory Block Level After Spinal Anesthesia Recruiting NCT03164096 Phase 4 Bupivacaine Hydrochloride
49 EC PK in Women With Normal and Obese BMI Completed NCT02689804 Phase 4 LNG-EC;UPA-EC
50 Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix Recruiting NCT03202381 Phase 4 Degarelix

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

42
Breast, Heart, Liver, Ovary, Kidney, Prostate, Testes

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 4913)
# Title Authors Year
1
Prognostic Value of Combined C-Reactive Protein, Body Mass Index, and Left Ventricular Ejection Fraction in Predicting Cardiovascular Events in Patients ≥80 Years of Age With Acute Myocardial Infarction. ( 30538036 )
2019
2
Body-mass index correlates with severity and mortality in acute pancreatitis: A meta-analysis. ( 30783376 )
2019
3
The association between body mass index and testosterone deficiency in aging Chinese men with benign prostatic hyperplasia: results from a cross-sectional study. ( 31058560 )
2019
4
Effect of aging, menopause, and age at natural menopause on the trend in body mass index: a 15-year population-based cohort. ( 30929733 )
2019
5
Association of body mass index and season with histamine skin reactivity in Chinese children with allergic rhinitis. ( 29983339 )
2019
6
Associations between interoceptive sensitivity, intuitive eating, and body mass index in patients with anorexia nervosa and normal-weight controls. ( 30968474 )
2019
7
Indirect and direct measures of striving for perfection moderate body mass index curves in the intensive treatment of anorexia nervosa. ( 30009415 )
2019
8
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. ( 31053871 )
2019
9
Causal association between body mass index and risk of rheumatoid arthritis: A Mendelian randomization study. ( 30710354 )
2019
10
Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis. ( 30953786 )
2019
11
Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. ( 30898691 )
2019
12
Body mass index and body fat distribution and new-onset atrial fibrillation: Substudy of the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. ( 31079869 )
2019
13
Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China atrial fibrillation registry study. ( 30953181 )
2019
14
Weight and Risk of Incident Atrial Fibrillation-Body Mass Index Variability or Body Mass Gain? ( 30711114 )
2019
15
Body Mass Index Variability and Long-term Risk of New-Onset Atrial Fibrillation in the General Population: A Korean Nationwide Cohort Study. ( 30711120 )
2019
16
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. ( 30624719 )
2019
17
Levels and Changes in Childhood Body Mass Index in Relation to Risk of Atrial Fibrillation and Atrial Flutter in Adulthood. ( 30649157 )
2019
18
Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). ( 30527775 )
2019
19
Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. ( 30279268 )
2019
20
Attention-deficit hyperactivity disorder symptomatology, binge eating disorder symptomatology, and body mass index among college students. ( 31009328 )
2019
21
Sex and racial/ethnic differences in the association between childhood attention-deficit/hyperactivity disorder symptom subtypes and body mass index in the transition from adolescence to adulthood in the United States. ( 30629806 )
2019
22
A Prospective Cohort Study of the Association Between Body Mass Index and Incident Bacterial Vaginosis. ( 30148757 )
2019
23
Body mass index and diabetes are important prognostic signatures for bilateral breast cancer prognosis. ( 30618092 )
2019
24
Pre-pregnancy body mass index and the risk of antenatal depression and anxiety. ( 30733069 )
2019
25
Association of body mass index with bladder cancer risk in men depends on abdominal obesity. ( 30806768 )
2019
26
Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause. ( 30666489 )
2019
27
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. ( 29992381 )
2019
28
The effect of body mass index on the functional prognosis of traumatic brain injury patients. ( 30689301 )
2019
29
Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. ( 31028608 )
2019
30
Association of white blood cell count with breast cancer burden varies according to menopausal status, body mass index, and hormone receptor status: a case-control study. ( 30962496 )
2019
31
Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. ( 30944014 )
2019
32
Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. ( 30929013 )
2019
33
Body Mass Index at Diagnosis as a Prognostic Factor for Early-Stage Invasive Breast Cancer after Surgical Resection. ( 30852575 )
2019
34
Prospective Longitudinal Patient-Reported Satisfaction and Health-Related Quality of Life Following DIEP Flap Breast Reconstruction: Relationship with Body Mass Index. ( 30907803 )
2019
35
Body mass index impacts infection rates in immediate autogenous breast reconstruction. ( 30937658 )
2019
36
The Effect of Smoking and Body Mass Index on The Complication Rate of Alloplastic Breast Reconstruction. ( 30712467 )
2019
37
One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty. ( 30699070 )
2019
38
Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. ( 30871884 )
2019
39
The relationship between body mass index, sex, and postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer. ( 30904219 )
2019
40
Transcriptome Profiles of Human Visceral Adipocytes in Obesity and Colorectal Cancer Unravel the Effects of Body Mass Index and Polyunsaturated Fatty Acids on Genes and Biological Processes Related to Tumorigenesis. ( 30838002 )
2019
41
The association between body mass index and postoperative complications, 30-day mortality and long-term survival in Dutch patients with colorectal cancer. ( 30712552 )
2019
42
Clinical Significance of Gender and Body Mass Index in Asian Patients with Colorectal Cancer. ( 30719166 )
2019
43
BODY MASS INDEX AND ALBUMIN LEVELS ARE ASSOCIATED WITH PULMONARY FUNCTION PARAMETERS IN PEDIATRIC SUBJECTS WITH CYSTIC FIBROSIS. ( 31090852 )
2019
44
Impaired glucose tolerance, body mass index and respiratory function in patients with cystic fibrosis: A systematic review. ( 30919537 )
2019
45
Body mass index and dental caries experience in Nepalese schoolchildren. ( 31094008 )
2019
46
Dental caries experience in relation to body mass index and anthropometric measurements of rural children of Nellore district: A cross-sectional study. ( 30804302 )
2019
47
The potential impact of age, gender, body mass index, socioeconomic status and dietary habits on the prevalence of dental caries among Egyptian adults: a cross-sectional study. ( 30906540 )
2019
48
Association between Dental Caries and Body Mass Index-for-Age among 10-12-Year-Old Female Students in Tehran. ( 30967914 )
2019
49
Body mass index and dental caries in young people: a systematic review. ( 31014292 )
2019
50
Relationships among Body Mass Index, Body Image, and Depression in Korean Adults: Korea National Health and Nutrition Examination Survey 2014 and 2016. ( 31089581 )
2019

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....